Olaparib: New Standard for BRCA-Mutated Breast Cancer? Olaparib: New Standard for BRCA-Mutated Breast Cancer?

The PARP inhibitor olaparib (Lynparza) showed significant benefit in patients with HER2-negative metastatic breast cancer with a BRCA mutation.Medscape Medical News

Source: Medscape Medical News Headlines - June 4, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news